Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Therapeutic Targets for Neurodevelopmental Disorders Emerging from Animal Models with Perinatal Immune Activation.

Ibi D, Yamada K.

Int J Mol Sci. 2015 Nov 27;16(12):28218-29. doi: 10.3390/ijms161226092. Review.

2.

Matrix metalloproteinase-3 is a possible mediator of neurodevelopmental impairment due to polyI:C-induced innate immune activation of astrocytes.

Yamada S, Nagai T, Nakai T, Ibi D, Nakajima A, Yamada K.

Brain Behav Immun. 2014 May;38:272-82. doi: 10.1016/j.bbi.2014.02.014. Epub 2014 Mar 1.

PMID:
24594387
3.

Autoantibodies from schizophrenia patients induce cerebral cox-1/iNOS mRNA expression with NO/PGE2/MMP-3 production.

Ganzinelli S, Borda E, Sterin-Borda L.

Int J Neuropsychopharmacol. 2010 Apr;13(3):293-303. doi: 10.1017/S1461145709990770. Epub 2009 Oct 19.

PMID:
19835666
4.

Do schizophrenia and bipolar disorders share a common disease susceptibility variant at the MMP3 gene?

Kucukali CI, Aydin M, Ozkok E, Bilge E, Orhan N, Zengin A, Kara I.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):557-61. doi: 10.1016/j.pnpbp.2009.02.012. Epub 2009 Feb 23.

PMID:
19245826

Supplemental Content

Loading ...
Support Center